Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study

Affiliations

• ¹ Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
• ² Hematology Division, Department of Internal Medicine, University of Patras, Medical School, Patras, Greece.
• ³ Department of Hematology and Bone Marrow Transplantation Unit, Evangelismos Hospital, Athens, Greece.
• ⁴ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
• ⁵ Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
• ⁶ Department of Hematology, Theagenio Cancer Hospital, Thessaloniki, Greece.
• ⁷ Department of Hematology, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
• ⁸ First Department of Propedeutic Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
• ⁹ First Department of Internal Medicine, Division of Hematology, AHEPA University Hospital, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece.
• ¹⁰ Health Data Specialists, Dublin, Ireland.